Sustained Improvements in Quality of Life With Secukinumab in Ankylosing Spondylitis

The following article is part of conference coverage from the 2018 American College of Rheumatology and Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting in Chicago, Illinois. Rheumatology Advisor’s staff will be reporting breaking news associated with research conducted by leading experts in rheumatology. Check back for the latest news from ACR/ARHP 2018 .

CHICAGO – In patients with ankylosing spondylitis (AS), treatment with secukinumab 150 mg provides significant, clinically meaningful, and sustained improvement in health-related quality of life, as assessed by the Short Form-36 (SF-36) Health Survey. The results of a pooled analysis from the phase 3 trials (ClinicalTrials.gov identifiers: NCT01358175, NCT01649375, NCT02159053) were presented at the 2018 ACR/ARHP Annual Meeting, held October 19-24, 2018, in Chicago, Illinois.

Patients with active AS were randomly assigned to receive intravenous secukinumab 10 mg/kg followed by subcutaneous 150 mg or 75 mg, subcutaneous secukinumab 150 or 75 mg, subcutaneous secukinumab 150 mg with or without a loading dose, or placebo for 16 weeks. Participants were stratified according to prior tumor necrosis factor (TNF) inhibitor therapy.

At 16 weeks, those receiving placebo were switched to secukinumab. The proportions of patients who reported improvements meeting or exceeding the minimal clinically important differences for SF-36 physical component summary, mental component summary, and individual SF-36 domains were evaluated.

A total of 743 patients were included in the study, 430 of whom received secukinumab 150 mg and 313 of whom received placebo. Approximately 30% had an inadequate response to TNF inhibitors. The least squares mean changes from baseline to 16 weeks in SF-36 were significantly greater with secukinumab 150 mg vs placebo for the physical component summary (6.09 vs 2.75, respectively; P <.0001), mental component summary (4.40 vs 2.45, respectively; P <.01), and all individual domain scores.

Similar significant improvements were reported with secukinumab 150 mg compared with placebo in TNF-naive patients at 16 weeks (physical component summary: 7.23 vs 3.40, respectively; P <.0001; mental component summary: 5.22 vs 2.92, respectively; P <.01). Among patients with inadequate response to TNF inhibitors, the physical component summary score was significantly improved with secukinumab 150 mg vs placebo at 16 weeks (4.79 vs 2.44, respectively; P <.05). A significantly higher proportion of physical component summary responders were in the secukinumab 150-mg group compared with the placebo group at 16 weeks, regardless of TNF status.

For more coverage of ACR/ARHP 2018, click here.

Reference

Deodhar AA, Boonen A, Ferraccioli G, et al. Secukinumab provides early and sustained improvements in health-related quality of life in patients with ankylosing spondylitis: a pooled analysis from the secukinumab phase 3 trial program. Presented at: 2018 ACR/ARHP Annual Meeting; October 19-24, 2018; Chicago, IL. Abstract 2583.

This information is brought to you by Haymarket Media and is not sponsored by, nor a part of, the American College of Rheumatology.